Managing Director & Senior Biotechnology Analyst
TD Securities
Ritu Baral joined TD Securities in August 2014 as a senior biotechnology
analyst and managing director. Ms. Baral has more than nineteen years of
experience in biotechnology finance, including over sixteen years in
biotechnology equity research. Her coverage has focused on rare diseases
and neurology. From August 2006 until June 2014, she held a series of
positions in biotechnology equity research at Canaccord Genuity, including
senior analyst and managing director. Before that, Ms. Baral was an equity
research associate at JMP Securities and a senior associate at the Trout
Group. Previously, she was a research associate at Columbia University’s
Department of Medicine, where she participated in neuroendocrine
research focused on appetite and metabolism regulation, and completed
graduate coursework in immunology.
Ms. Baral graduated with a BA in biological sciences from Barnard College.
She is involved in a number of rare disease patient advocacy organizations,
including as a board member of the Everylife Foundation for Rare Disease
and the Industry Advisory Board of the National Tay-Sachs and Allied
Diseases Foundation. She was previously on the board of directors of the
Pulmonary Fibrosis Foundation.